EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers

Yu Zhang iD, Ke Qiu, Jiayuan Ai, Maosen Xu, Binhan Wang, Aqu Alu, Chunjun Ye, Xiya Huang, Yu Zhang, Yingqiong Zhou, Zhiruo Song, Jie Shi und 6 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Yu Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Cancer Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University, the National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐risk human papillomavirus (HPV), especially HPV16, is closely correlated with certain cancers. E6 and E7 proteins of HPV16 play critical roles in oncogenesis, making them optimal targets for treating HPV‐associated cancers. Here, we engineered an innovative vaccine, Ad‐E6/7‐HR, designed to evoke immune responses through the incorporation of self‐assembling heptad‐repeat 1 (HR1) and HR2 originated from Severe acute respiratory syndrome coronavirus 2.

Methods

Ad‐E6/7‐HR was constructed utilising a replication‐defective human adenovirus serotype 5 vector and evaluated its immunogenicity and therapeutic efficacy in murine models. We verified the antitumour efficacy of the vaccine in TC‐1 subcutaneous and pulmonary models. Flow cytometry, enzyme‐linked immunospot assay, and immunofluorescence staining were used to assess the cellular immunogenicity of Ad‐E6/7‐HR.

Results

Ad‐E6/7‐HR induced robust immune responses, significantly increasing antigen‐specific CD8 + T cells. The vaccine also enhanced memory T‐cell generation and induced potent cytokine secretion, as exemplified by interferon‐γ and tumour necrosis factor‐α. Ad‐E6/7‐HR conferred complete protection against tumour growth in the prophylactic model. In therapeutic settings, Ad‐E6/7‐HR significantly reduced tumour size and improved survival. Furthermore, Ad‐E6/7‐HR reshaped the tumour microenvironment by increased CD8 + T‐cell recruitment and reduced immunosuppressive cells, like myeloid‐derived suppressor cells and M2 macrophages, thereby enhancing antitumour immunity.

Conclusions

By targeting HPV16 E6 and E7 proteins and leveraging the self‐assembling HR1 and HR2 sequences to enhance immune responses, Ad‐E6/7‐HR represented a promising candidate for preventing and treating HPV‐associated cancers. Further clinical investigation is warranted to evaluate its potential in human trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsPapillomavirus VaccinesCancer VaccinesAnimalsMiceHumansFemaleOncogene Proteins, ViralPapillomavirus E7 ProteinsHuman papillomavirus 16Repressor Proteins

Stichwörter der Autor:innen

adenovirus vaccinecellular immunityhuman‐papillomavirus‐associated cancersoncology

Substanzen

Oncogene Proteins, ViralPapillomavirus VaccinesPapillomavirus E7 ProteinsE6 protein, Human papillomavirus type 16Cancer VaccinesRepressor Proteins

Autor:innen und Institutionen

  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Otolaryngology-Head & Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Yu Zhang, Xiawei Wei

Förderung

  • 1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University
  • the National Key Research and Development Program of China

Zitieren

APA

Zhang, Y., Qiu, K., Ai, J., Xu, M., Wang, B., Alu, A., Ye, C., Huang, X., Zhang, Y., Zhou, Y., Song, Z., Shi, J., Lu, Y., Wei, Y., Ren, J., Zhao, Y., Cheng, P., & Wei, X. (2025). Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70305

Vancouver

Zhang Y, Qiu K, Ai J, Xu M, Wang B, Alu A, et al. Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70305

BibTeX
@article{Zhang2025,
  author = {Zhang, Yu and Qiu, Ke and Ai, Jiayuan and Xu, Maosen and Wang, Binhan and Alu, Aqu and Ye, Chunjun and Huang, Xiya and Zhang, Yu and Zhou, Yingqiong and Song, Zhiruo and Shi, Jie and Lu, Yishan and Wei, Yuquan and Ren, Jianjun and Zhao, Yu and Cheng, Ping and Wei, Xiawei},
  title = {Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70305}
}
Kostenlos starten →